Xenetic Biosciences reports Q2 results (NASDAQ:XBIO)
Net loss for the quarter ended June 30, 2026, was approximately $0.9 million, compared to approximately $0.7 million for the same period in 2025. The Company ended the second quarter of 2026 with approximately $6.5 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025. ...